Drug Profile
Research programme: histone deacetylase inhibitors - Pharmacyclics
Alternative Names: CRA-026440; PCI-34051Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Celera Genomics Group
- Developer Pharmacyclics
- Class Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 26 May 2015 Pharmacyclics has been acquired by AbbVie
- 01 Oct 2014 No development reported - Preclinical for Autoimmune disorders in USA (PO)